Michael Petusky, an analyst from Barrington, maintained the Buy rating on US Physical Therapy. The associated price target remains the same with $103.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Petusky has given his Buy rating due to a combination of factors, including U.S. Physical Therapy’s strong financial performance in the third quarter. The company reported total revenue of $197.1 million, surpassing both the firm’s and consensus estimates. This growth was driven by a significant increase in patient revenue and a robust performance in the industrial injury prevention business.
Additionally, the company’s profitability metrics exceeded expectations, with adjusted EPS and EBITDA both coming in higher than anticipated. The solid top-line performance, coupled with effective expense management, contributed to these results. Furthermore, U.S. Physical Therapy reaffirmed its adjusted EBITDA guidance for the fiscal year, indicating confidence in its ongoing financial stability. Petusky maintains an OUTPERFORM rating with a price target of $103, reflecting a 33% upside potential.